BeiGene BGB-3111-212 An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma
Administered By
Awarded By
Contributors
- McKinney, Matthew Stuart Principal Investigator
Start/End
- June 26, 2018 - July 14, 2023